Paper: Real-World Outcomes with Fedratinib Therapy in Patients Who Discontinued Ruxolitinib for Primary Myelofibrosis -

Oral and Poster Abstracts 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III Adults, Clinical Research, Real World Evidence, Therapies, Study Population Francesco Passamonti, MD1*, Quynh Do, PhD, MPH2*, Youbei Lou, PhD2*, Manoj Chevli, MSc3* and Pranav Abraham, PhD2*1University of Insubria and ASST Sette Laghi, Varese,...